金叶败毒颗粒联合克拉霉素治疗急性上呼吸道感染疗效观察

The Therapeutic Effect of Jinyebaidu Granule Combined with Clarithromythin in Acute Upper Respiratory Tract Infection

目的:比较金叶败毒颗粒与利巴韦林颗粒联合克拉霉素缓释片治疗急性上呼吸道感染的临床疗效及安全性。方法:将急性上呼吸道感染82例患者随机分为治疗组42例与对照组40例,均给予口服克拉霉素缓释片基础上,治疗组加用金叶败毒颗粒,对照组加用利巴韦林颗粒,疗程3～7d。结果:治疗组总有效率95.2%,对照组总有效率77.5%,两组差异有显著性(P<0.05),治疗组在治疗后平均退热天数及鼻塞流涕、咽喉疼痛、咳嗽等症状平均消失天数均较对照组显著缩短(P<0.05),两组无不良反应发生。结论:金叶败毒颗粒联合克拉霉素缓释片治疗急性上呼吸道感染疗效显著,安全可靠。

Objective：To compare the efficacy and safety of either Jinyebaidu granule or ribavirin combined with clarithromythin in the treatment of acute upper respiratory tract infection.Methods：82 patients suffering from acute upper respiratory tract infection were randomly divided into treated group（n=42） and control group（n=40）.Besides taking clarithromythin,42 patients in the treated group were administered Jinyebaidu granule,while 40 patients in the control group were administered ribavirin.The therapy lasted 3～7 days.Results：The rates of effectiveness in treated group and control group were 95.2% and 77.5% respectively,which were statistically significant（P〈0.05）.In comparison to the control group,the average duration of such symptoms as fever,sore throat and cough in the treated group were significantly reduced（P〈0.05）.No side effects were recorded in both groups during the treatment.Conclusion：Jinyebaidu granucle combined with clarithromythin is efficacious and safe in the treatment of acute upper respiratory tract infection.